ExpreS2ion Biotech Holding AB (SE:EXPRS2)

:EXPRS2

EXPRS2

ExpreS2ion Biotech Holding AB

RESEARCH TOOLSreports

ExpreS2ion Biotech Holding AB (EXPRS2) Price & Analysis

0 Followers

EXPRS2 Stock Chart & Stats

kr17.10

-kr1.20(-4.51%)

At close: Mar 06 4:00 PM EST

kr17.10

-kr1.20(-4.51%)

Day’s Range― - ―

52-Week Rangekr3.82 - kr34.20

Previous CloseN/A

Volume135.00

Average Volume (3M)19.88K

Market Cap

kr19.56M

Enterprise Value-kr30.62M

Total Cash (Recent Filing)kr47.55M

Total Debt (Recent Filing)kr2.21M

Price to Earnings (P/E)―

Beta1.33

Next Earnings

May 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.41

Shares Outstanding3,530,233

10 Day Avg. Volume26,629

30 Day Avg. Volume19,883

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)1.27

Price to Sales (P/S)12.37

P/FCF Ratio-1.11

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-27

Revenue Forecast (FY)kr10.00M

Bulls Say, Bears Say

Bulls Say

Proprietary Expression PlatformThe ExpreS2 insect-cell platform is a durable competitive asset: it enables production of complex antigens and VLPs that many labs struggle to make. This technical capability creates repeatable service revenue, partner interest, and a barrier to entry that supports long-term platform monetization.

Low Financial LeverageDebt levels around 2–3% of equity provide meaningful financial flexibility for a small biotech. Low leverage reduces interest burden and preserves options to pursue R&D, partnerships or selective financing during lengthy development cycles without immediate distress.

Reported Revenue GrowthA reported ~21% revenue growth metric indicates periods of commercial traction for platform services. If sustained through recurring service contracts and partnerships, this top-line momentum can reduce funding reliance and enable incremental scaling of lab services and program development.

Bears Say

Negative Cash FlowConsistent negative operating and free cash flow is a structural constraint: the business consumes cash rather than generating it. The 2025 FCF deterioration (~13% YoY) highlights ongoing burn and implies continued dependence on external funding absent sustained revenue scale or material cost reduction.

Persistent LossesSizable operating and net losses each year produce deeply negative margins and no self-funding path. Persistent unprofitability elevates dilution risk from future capital raises, constrains reinvestment in programs, and increases execution risk for advancing internal vaccine candidates long term.

Eroding Equity BaseMaterial contraction in equity and total assets over multiple years signals cumulative losses that weaken the balance sheet. Reduced asset and equity cushions limit borrowing headroom, reduce resilience to setbacks, and constrain the firm's ability to finance development or scale operations without dilution.

EXPRS2 FAQ

What was ExpreS2ion Biotech Holding AB’s price range in the past 12 months?

ExpreS2ion Biotech Holding AB lowest stock price was kr3.81 and its highest was kr34.20 in the past 12 months.

What is ExpreS2ion Biotech Holding AB’s market cap?

ExpreS2ion Biotech Holding AB’s market cap is kr19.56M.

When is ExpreS2ion Biotech Holding AB’s upcoming earnings report date?

ExpreS2ion Biotech Holding AB’s upcoming earnings report date is May 28, 2026 which is in 46 days.

How were ExpreS2ion Biotech Holding AB’s earnings last quarter?

ExpreS2ion Biotech Holding AB released its earnings results on Feb 19, 2026. The company reported -kr2.406 earnings per share for the quarter, missing the consensus estimate of N/A by -kr2.406.

Is ExpreS2ion Biotech Holding AB overvalued?

According to Wall Street analysts ExpreS2ion Biotech Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ExpreS2ion Biotech Holding AB pay dividends?

ExpreS2ion Biotech Holding AB does not currently pay dividends.

What is ExpreS2ion Biotech Holding AB’s EPS estimate?

ExpreS2ion Biotech Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ExpreS2ion Biotech Holding AB have?

ExpreS2ion Biotech Holding AB has 3,530,233 shares outstanding.

What happened to ExpreS2ion Biotech Holding AB’s price movement after its last earnings report?

ExpreS2ion Biotech Holding AB reported an EPS of -kr2.406 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.29%.

Which hedge fund is a major shareholder of ExpreS2ion Biotech Holding AB?

Currently, no hedge funds are holding shares in SE:EXPRS2

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ExpreS2ion Biotech Holding AB

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.